KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $117.5 million.

  • Halozyme Therapeutics' Shares Outstanding fell 759.54% to $117.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.5 million, marking a year-over-year decrease of 759.54%. This contributed to the annual value of $123.1 million for FY2024, which is 286.5% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Shares Outstanding of $117.5 million as of Q3 2025, which was down 759.54% from $117.6 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Shares Outstanding high stood at $143.4 million for Q1 2021, and its period low was $117.5 million during Q3 2025.
  • Its 5-year average for Shares Outstanding is $131.3 million, with a median of $131.9 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Shares Outstanding skyrocketed by 592.18% in 2021 and then crashed by 759.54% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Shares Outstanding stood at $137.5 million in 2021, then dropped by 1.7% to $135.2 million in 2022, then dropped by 6.2% to $126.8 million in 2023, then fell by 2.87% to $123.1 million in 2024, then fell by 4.56% to $117.5 million in 2025.
  • Its last three reported values are $117.5 million in Q3 2025, $117.6 million for Q2 2025, and $123.2 million during Q1 2025.